18 November 2015
£12,000 Worth of Vet Bursary Funds Awarded
MILTON KEYNES, UK, November 18 2015 – Three UK vets have received £4,000 each from MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA.) to finance field-based ruminant research projects. The Ruminant Research Bursary award is designed to encourage practical on-farm research related to ruminant disease challenges that significantly impact on the profitability of UK livestock.
Jonathan Statham from Bishopton Veterinary Group in North Yorkshire, Rachel Clifton from the University of Warwick and Andrea Turner from the University of Bristol were presented with their cheques at the BCVA Congress last month. Their project findings will be presented at a future BCVA Congress.
Previous winner of the award Kathryn Hart says: “The ruminant research bursary provides vets in practice with a fantastic opportunity to undertake practical field study work in to a subject you are passionate about. All-too-often veterinary research tends to focus on the needs of the scientific establishment rather than farmers. It also gives you an edge with clients. When talking to farmers it’s so much better to be drawing on findings of practical investigations you have done personally. Farmers really do appreciate this applied scientific insight into health issues they are managing on a day-to-day basis.”
MSD Animal Health is now inviting applications for 2016 funding with two ruminant research bursaries available specifically for field study projects in the cattle youngstock arena.
Vets interested in applying have until 31 December 2015 to submit a project proposal. To register your interest and for further information e-mail: firstname.lastname@example.org
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to theScience of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).